Quel est le prix pour Homology Medicines, Inc. (FIXX)

Le prix pour Homology Medicines, Inc. (FIXX) est $0.9347

Quelle est la capitalisation boursière pour Homology Medicines, Inc. (FIXX)

La capitalisation boursière pour Homology Medicines, Inc. (FIXX) est $300.42K

Homology Medicines, Inc. (FIXX) Prix et Capitalisation Boursière

Homology Medicines, Inc. is a biotechnology firm dedicated to genetic therapeutics, striving to enhance the well-being of patients battling rare inherited disorders. The company leverages its unique platform, which employs adeno-associated virus vectors (AAVHSCs) originating from human hematopoietic stem cells, to introduce genetic treatments directly into the body. This approach facilitates either gene therapy or nuclease-free gene editing solutions for a range of genetic ailments. Crucially, Homology's diverse collection of AAVHSCs enables the precise targeting of multiple disease-affected tissues—such as the liver, central and peripheral nervous systems, bone marrow, heart, skeletal muscles, and eyes—all from a single administration. The leading candidate in their pipeline, HMI-102, is a gene therapy undergoing the Phase 2 pheNIX clinical trial, intended for adult patients with phenylketonuria (PKU). Beyond this, their development portfolio includes HMI-103 for pediatric PKU, HMI-202 targeting metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 designed to address paroxysmal nocturnal hemoglobinuria. Established in 2015, Homology Medicines, Inc. maintains its corporate headquarters in Bedford, Massachusetts.

Prix pour FIXX	L’actif B	La capitalisation boursière de B	Résultats
$17,017,535 $300.42K	NVDA	$5.470T	+1,820,641,256.89%
$13,898,531 $300.42K	AAPL	$4.467T	+1,486,950,883.24%
$12,987,892 $300.42K	GOOG	$4.174T	+1,389,525,078.69%
$11,512,160 $300.42K	MSFT	$3.700T	+1,231,642,142.33%
$8,880,801 $300.42K	AMZN	$2.854T	+950,123,032.23%

Prix pour FIXX

L’actif B

La capitalisation boursière de B

Résultats

$17,017,535 $300.42K